Integra LifeSciences

Integra LifeSciences was founded by Richard Caruso in 1989 after Caruso licensed Integra artificial skin technology from Harvard–MIT and acquired Colla-tec, a subsidiary of Marion Laboratories. The company became publicly traded under the NASDAQ ticker name IART. The artificial skin, manufactured and patented as Integra, is now used on patients with extensive burns. In 2001, NMT, a company acquired by Integra in 2002, received FDA approval for Licox, a brain tissue oxygen and temperature monitor. Licox is used to treat patients in critical care, including those suffering from traumatic brain injuries. In 2016, IDRT received premarket approval from the FDA for the treatment of diabetic foot ulcers. In 2018, Integra LifeSciences was included in Fortune’s list of Fastest Growing Companies. In 2023, Integra ranked #59 on Medical Design and Outsourcing’s list of largest medical technology companies in the world. == Integra artificial skin ==

In 1969, John F. Burke, a surgeon and Harvard Medical School professor, and Ioannis V. Yannas, a mechanical engineering professor of fibers and polymers at MIT, began working on a new form of artificial skin. Compared to traditional skin grafts, the use of Integra reduces pain and scarring. == Acquisitions ==

In October 2014, Integra LifeSciences acquired instrumentation lines from Medtronic for $60 million. In January 2014, the company bought Covidien’s Confluent Surgical line of sealants and shields. In July 2015, Integra LifeSciences acquired TEI Biosciences and TEI Medical and began manufacturing their SurgiMend and PriMatrix product lines. Primatrix, a dermal repair scaffolding product, is used to treat diabetic foot ulcers, burns, and in other procedures. In January 2017, Integra Lifesciences acquired Derma Sciences for $204 million. Their TCC-EZ Total Contact Cast, used to treat diabetic foot ulcers, reduces pressure and shortens application time compared to a conventional total contact cast. In October 2017, Integra LifeSciences acquired Johnson & Johnson’s Codman Neurosurgery business for $1.045 billion. The Codman Hakim valve was developed as a new way to treat hydrocephalus. In January 2021, the company acquired regenerative medicine firm, ACell, for $400M. In April 2024, Integra completed the acquisition of Acclarent. ==References==